Haemonetics' President and CEO, Chris Simon, was featured on this week’s episode of Vanguards of Health Care by Bloomberg Intelligence. Listen to Chris discuss the company’s solutions, growth and evolution in the #MedTech industry here: https://bit.ly/3XlBZYn
About us
Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics, visit www.haemonetics.com.
- Website
-
http://www.haemonetics.com
External link for Haemonetics
- Industry
- Medical Equipment Manufacturing
- Company size
- 1,001-5,000 employees
- Headquarters
- Boston, MA
- Type
- Public Company
- Founded
- 1971
- Specialties
- Blood collection and separation technologies, surgical blood salvage systems, diagnostic products, software and information technology platforms, consulting services, interventional technologies, and plasma collection products
Locations
-
Primary
Boston, MA 02110, US
Employees at Haemonetics
Updates
-
Haemonetics is proud to work with many of the hospitals listed on this year’s U.S. News and World Report #BestHospitals Honor Roll list 2024-2025: https://bit.ly/3hLPUyX #MakeItMatter
-
Happy #NationalInternDay! Thank you to the hard-working students who are #MakingItMatter with team Haemonetics this summer in our Boston, MA and Clinton, PA offices!
-
-
The Association for Diagnostics & Laboratory Medicine Conference kicks off this Sunday in Chicago, IL. Stop by Haemonetics booth #1232 to learn more about our TEG® 6s System and Transfusion Management Software. We can’t wait to see you there! #ADLM20204
-
-
Knowing the work we do can help to improve patient care drives our team to do their very best every day. #MakeItMatter #InternLifeAtHAE
-
-
As our interns learn the ins and outs of being part of a global #MedTech organization, they can find ways to apply their existing skills, while building new ones, in a dynamic atmosphere. #MakeItMatter #InternLifeAtHAE
-
-
Primary Immunodeficiency (PID) is a chronic disease, meaning those with it require specific care for the rest of their lives. A common treatment for PID is medicine derived from blood plasma. If you can, consider donating for #ChronicDiseaseAwarenessDay: https://bit.ly/33cPE8f
-
-
Haemonetics' internship program allows students to get hands on experience with real-world projects that help them develop relevant, applicable skills. #MakeItMatter #InternLifeAtHAE
-
-
Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2025 Results: August 8, 2024: https://bit.ly/3S0LUPF
Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2025 Results: August 8, 2024 | Haemonetics Corporation
haemonetics.gcs-web.com
-
Our interns are motivated by the impact Haemonetics' products and solutions can have on patient care. #MakeItMatter #InternLifeAtHAE
-
Affiliated pages
Similar pages
Browse jobs
Stock
HAE
NYSE
20 minutes delay
$89.74
-1.32 (-1.45%)
- Open
- 91.3
- Low
- 88.5
- High
- 91.88
Data from Refinitiv
See more info on